How to read: Every bubble is one Indian efavirenz exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Efavirenz report covers
KEY TAKEAWAYEvery figure in this report is grounded in real commercial efavirenz trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian efavirenz suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Efavirenz India trade report
P
Product scope
Efavirenz
All variants merged — branded and generic formulations of efavirenz
T
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
S
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
G
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
C
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
R
Shipments analysed
47
Every commercial efavirenz trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY2025-Q4 followed a steady rise: Oct $106.6K, Nov $468.3K, Dec $793.2K. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$106.6K
Oct USD
1 shipments
2
$468.3K
Nov USD
+339.3% MoM
3
$793.2K
Dec USD
+69.4% MoM
4
Steady rise
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov rose 339.3% in USD but shipment count kept climbing.
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $107K, making it the weakest month by value.
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: MACLEODS PHARMACEUTICALS LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import efavirenz from India, how much they buy, and who supplies each market
KEY TAKEAWAYAlgeria absorbs 28.5% of India’s 2025-Q4 efavirenz trade ($390.3K). Beyond the top 10 destinations, 18 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Africa has 7 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 18 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much efavirenz India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$462K
33.8% of trade
7 countries · 15 shipments
Americas
$428K
31.3% of trade
4 countries · 8 shipments
Africa
$478K
35.0% of trade
7 countries · 24 shipments
Fig 4.1 Algeria is the #1 corridor ($390K) — 18 flow arcs from India radiate across 3 continents.
How to read: The world map shows every country colored by how much Indian efavirenz it receives (light = low, dark = high). Orange arcs radiate from India to the top 18 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
#
Destination
Total USD
Ships
#1 Indian supplier
USD
#2 Indian supplier
USD
#3 Indian supplier
USD
1
Algeria
$390K
12
CIPLA LTD
$270K
MACLEODS PHARMACEUTICALS LTD
$120K
—
—
2
United States
$231K
3
AUROBINDO PHARMA LTD
$231K
—
—
—
—
3
Vietnam
$230K
4
MACLEODS PHARMACEUTICALS LTD
$230K
—
—
—
—
4
Trinidad and Tobago
$140K
3
MACLEODS PHARMACEUTICALS LTD
$140K
—
—
—
—
5
Myanmar
$117K
3
CIPLA LTD
$117K
MICRO LABS LTD
$344
—
—
6
Malaysia
$107K
1
MYLAN LABORATORIES LTD
$107K
—
—
—
—
7
Colombia
$56K
1
AUROBINDO PHARMA LTD
$56K
—
—
—
—
8
Tanzania
$44K
4
MACLEODS PHARMACEUTICALS LTD
$44K
—
—
—
—
9
Morocco
$28K
1
SUN PHARMACEUTICAL INDUSTRIES LTD
$28K
—
—
—
—
10
Eritrea
$8K
1
MACLEODS PHARMACEUTICALS LTD
$8K
—
—
—
—
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 33.8% of USD — but Algeria is the single largest market.
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
28.5%
#1 country share
Algeria alone
81.0%
Top 5 share
5 of 18 countries
100.0%
Top 15 share
Long tail of 3 countries = 0.0%
HHI 1653
Destination HHI
Moderately concentrated
18
Countries served
Global pharma reach from India
7
Africa countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
10 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAYMACLEODS PHARMACEUTICALS LTD ($542.4K, 39.6% share) and CIPLA LTD ($392.6K) together control 68.3% of India’s 2025-Q4 efavirenz trade. The top 5 suppliers hold 99.2%. 10 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian efavirenz suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 MACLEODS PHARMACEUTICALS LTD leads by $150K over CIPLA LTD — top 10 Indian exporters ranked by trade value
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: DERRIC WOOD is #10 by value but #6 by volume.
Fig 5.2 MACLEODS PHARMACEUTICALS LTD also leads by shipment count (18) but ranking shifts for volume-heavy players
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: DERRIC WOOD moves from #6 by volume to #10 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 10 efavirenz suppliers split into strategic segments
KEY TAKEAWAY3 suppliers (25%) generate 89.3% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 MACLEODS PHARMACEUTICALS LTD and CIPLA LTD sit in the leaders zone — high volume AND high value.
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 89.3% of USD — classic concentration.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 3 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 4 destinations and up to 2 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
23 importers across 18 countries — who is buying Indian efavirenz and how much
KEY TAKEAWAYThe demand side is dramatically more fragmented than supply: the top 21 importers together hold only 87.7% of total USD. 96% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian efavirenz. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 AUROBINDO PHARMA USA. INC is the #1 importer at $202K (14.8%) — top 21 by trade value
How to read: Left semicircle = top 10 Indian suppliers; right = top 20 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian efavirenz prices vary by supplier, country and dosage form
KEY TAKEAWAYEfavirenz prices span 124894× ($0.0002 → $23.95). The coefficient of variation is 2.72. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. MACLEODS PHARMACEUTICALS LTDSourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. DERRIC WOODSourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. GNH INDIA PHARMACEUTICALSSourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAYExtreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Nov 2025
DERRIC WOOD
United Arab Emirates
Tablet
1
$23.95
$23.95
Specialty / small-batch
Nov 2025
DERRIC WOOD
United Arab Emirates
Tablet
1
$23.78
$23.78
Specialty / small-batch
Nov 2025
GNH INDIA PHARMA…
Singapore
Tablet
832
$8K
$9.60
Specialty / small-batch
Dec 2025
SIDDHIVINAYAK DI…
Guinea
Tablet
280
$2K
$6.17
Specialty / small-batch
Dec 2025
H V A INTERNATIO…
Guyana
Tablet
140
$692.53
$4.95
Specialty / small-batch
Nov 2025
MICRO LABS LTD
Myanmar
Tablet
103
$343.63
$3.34
Specialty / small-batch
Dec 2025
CIPLA LTD
Myanmar
Tablet
113K
$100K
$0.881
Dec 2025
CIPLA LTD
Myanmar
Tablet
19K
$17K
$0.881
Dec 2025
CIPLA LTD
Zambia
Tablet
11K
$5K
$0.440
Dec 2025
AUROBINDO PHARMA…
United States
Tablet
230K
$101K
$0.439
↓ TOP 10 LOWEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Dec 2025
SUN PHARMACEUTIC…
Azerbaijan
Tablet
15K
$17.47
$0.0012
Bulk generic tablet
Dec 2025
MACLEODS PHARMAC…
Azerbaijan
Tablet
33K
$49.33
$0.0015
Bulk generic tablet
Dec 2025
CIPLA LTD
Libya
Tablet
435K
$904.76
$0.0021
Bulk generic tablet
Dec 2025
CIPLA LTD
Libya
Tablet
239K
$497.32
$0.0021
Bulk generic tablet
Dec 2025
SUN PHARMACEUTIC…
Morocco
Tablet
362K
$28K
$0.078
Dec 2025
AUROBINDO PHARMA…
Colombia
Tablet
659K
$56K
$0.085
Dec 2025
MACLEODS PHARMAC…
Eritrea
Tablet
73K
$8K
$0.110
Dec 2025
MACLEODS PHARMAC…
Vietnam
Tablet
792K
$96K
$0.121
Dec 2025
MACLEODS PHARMAC…
Vietnam
Tablet
691K
$84K
$0.121
Nov 2025
MACLEODS PHARMAC…
Vietnam
Tablet
195K
$25K
$0.129
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
Dosage form is the #1 price driver, not destination
Light cells = easy-entry markets for small suppliers
Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship efavirenz, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAYEfavirenz leaves India through 6+ ports. The top 5 (DELHI AIR, MUMBAI AIR (SAHAR), HYDERABAD ICD) handle 100.0% of total USD. AIR moves 85% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 DELHI AIR handles $533K — top 6 Indian origin ports by trade value.
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
Route
Mode
Transit time
Notes
NHAVA SHEVA SEA (JNPT) → US East Coast
Sea
22–28 days
Via Suez; 2–3 transshipments typical
NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria)
Sea
18–24 days
Direct liner service available
MUMBAI AIR (SAHAR) → New York JFK
Air
3–5 days
Direct cargo; cold-chain available
MUNDRA SEA → Rotterdam
Sea
20–26 days
Via Suez; Hamburg also served
HYDERABAD AIR → London Heathrow
Air
2–4 days
Pharma-grade cargo corridor
CHENNAI SEA → Chittagong (Bangladesh)
Sea
7–12 days
Short-sea route; high frequency
RAXAUL → Birgunj (Nepal)
Road
1–2 days
Land border crossing
NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya)
Sea
14–20 days
Direct or via Colombo hub
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAYAIR dominates at 85% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
AIR
$958K
70.1% of USD · 85.1% of ships
ICD
$298K
21.8% of USD · 10.6% of ships
SEA
$111K
8.1% of USD · 4.3% of ships
Fig 8.3 The dominant corridor is MUMBAI AIR (SAHAR) → Air → Africa ($271K).
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAYVietnam is the most concentrated destination (HHI 10000, 1 suppliers). Algeria is the most competitive (HHI 5737).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Vietnam (HHI 10,000) is the most concentrated — Algeria (HHI 5,737) is the most competitive.
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 18 of 18 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
Buyer
Country
Sole supplier
USD
Ships
Risk
AUROBINDO PHARMA USA…
United States
AUROBINDO PHARMA…
$202K
2
HIGH
MINISTRY OF HEALTH
Trinidad and Tobago
MACLEODS PHARMAC…
$184K
7
HIGH
VIETNAM INTERNATIONA…
Vietnam
MACLEODS PHARMAC…
$180K
2
HIGH
PHARMACIE CENTRALE D…
Algeria
CIPLA LTD
$135K
4
HIGH
PHARMACIE CENTRALE D…
Algeria
MACLEODS PHARMAC…
$120K
4
HIGH
JDS CO LTD
Myanmar
CIPLA LTD
$117K
2
HIGH
PAHANG PHARMACY SDN …
Malaysia
MYLAN LABORATORI…
$107K
1
HIGH
AUROBINDO PHARMA COL…
Colombia
AUROBINDO PHARMA…
$56K
1
MEDIUM
Conclusion: 21 buyers depend on exactly one Indian supplier, representing $1.2M in trade. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
Buyer
Country
Suppliers
USD
Dominant
Resilience
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
Country
Tier
Lead
Price
Risk
Entry approach
Algeria
Tier 3 (emerging)
3–5 days (air)
$0.10–$1/unit
LOW
First-mover advantage
United States
Tier 3 (emerging)
3–5 days (air)
$0.10–$1/unit
LOW
First-mover advantage
Vietnam
Tier 3 (emerging)
3–5 days (air)
$0.10–$1/unit
LOW
First-mover advantage
Trinidad and Tobago
Tier 3 (emerging)
3–5 days (air)
$0.10–$1/unit
LOW
First-mover advantage
Myanmar
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Malaysia
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
Colombia
Tier 3 (emerging)
14–28 days (sea)
$0.01–$0.10/unit
LOW
First-mover advantage
Tanzania
Tier 3 (emerging)
3–5 days (air)
$0.01–$0.10/unit
LOW
First-mover advantage
Morocco
Tier 3 (emerging)
3–5 days (air)
$0.01–$0.10/unit
LOW
First-mover advantage
Eritrea
Tier 3 (emerging)
3–5 days (air)
$0.10–$1/unit
LOW
First-mover advantage
Singapore
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Zambia
Tier 3 (emerging)
14–28 days (sea)
$0.10–$1/unit
LOW
First-mover advantage
Guinea
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Libya
Tier 3 (emerging)
3–5 days (air)
$0.01–$0.10/unit
LOW
First-mover advantage
Guyana
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 15 in Fragile Dependency (concentrated + shrinking).
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAYQuick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
ID
Action
Timing
Impact
A1
Pitch top single-source buyer in United States
This Q
HIGH
A2
Offer alternative to top multi-source buyer
This Q
HIGH
A3
Audit Vietnam lock-ins (HHI 10000)
This Q
MED
A5
Enter Algeria (2 suppliers)
This Q
HIGH
A6
Enter United States (1 suppliers)
This Q
MED
A8
Build United States distribution
6–12m
HIGH
A9
Bundle injection/infusion catalog for premium markets
6–12m
MED
B
FOR BUYERS
ID
Action
Timing
Impact
A4
Monitor rising exporters (climbers)
This Q
MED
A7
Register for Algeria tenders
6–12m
HIGH
A10
Track quarterly HHI shifts across key destinations
This Q
LOW
A11
Map competitor buyer portfolios quarterly
This Q
MED
A12
Qualify second source for single-source buyers
This Q
MED
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
#
Country
Region
Suppliers
Q4 USD
Growth
Barrier
Why this is easy
1
Algeria
Africa
2
$390K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
2
United States
Other
1
$231K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
3
Vietnam
Asia
1
$230K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
4
Trinidad and Tobago
Other
1
$140K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
5
Myanmar
Asia
2
$117K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
6
Malaysia
Asia
1
$107K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
7
Colombia
Other
1
$56K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
8
Tanzania
Africa
1
$44K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
9
Morocco
Africa
1
$28K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
10
Eritrea
Africa
1
$8K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
11
Singapore
Asia
1
$8K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
12
Zambia
Africa
1
$5K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
13
Guinea
Africa
1
$2K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
14
Libya
Africa
1
$1K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
15
Guyana
Other
1
$693
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
This report covers 47 2025-Q4 Efavirenz shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/efavirenz
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAYThis section contains every one of the 47 2025-Q4 efavirenz shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian efavirenz shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
47
across all regions
TOTAL USD
$1.37M
2025-Q4 FOB value
UNITS
8.1M
tablets, capsules, etc.
SUPPLIERS
10
Indian exporters
BUYERS
23
global importers
COUNTRIES
18
destinations
§10.2 Regional breakdown
Africa
$478K
35.0%
7 ctry · 24 ships
Asia
$462K
33.8%
7 ctry · 15 ships
Americas
$428K
31.3%
4 ctry · 8 ships
§10.3 Key insights from the data
🌍
Africa is the largest region at $478K (35.0%), spanning 7 countries.
🏢
10 Indian suppliers shipped to 23 buyers across 18 countries — average shipment value $29K.
📄
Top 0 markets: .
🔍
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
All 21 global efavirenz importers — complete list ranked by USD
KEY TAKEAWAYThis directory lists every company that imported Indian efavirenz in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
#
Buyer
Country
Ships
USD
Primary supplier
Dosage forms
1
AUROBINDO PHARMA USA. INC
United States
2
$202K
AUROBINDO PHARMA LTD
Tablet
2
MINISTRY OF HEALTH
Trinidad and Tobago
7
$184K
MACLEODS PHARMACEUTI…
Other, Tablet
3
VIETNAM INTERNATIONAL COMMERCIAL
Vietnam
2
$180K
MACLEODS PHARMACEUTI…
Tablet
4
PHARMACIE CENTRALE DES HOPITAUX PCH
Algeria
4
$135K
CIPLA LTD
Capsule
5
PHARMACIE CENTRALE DES HOPITAUX
Algeria
4
$120K
MACLEODS PHARMACEUTI…
Tablet
6
JDS CO LTD
Myanmar
2
$117K
CIPLA LTD
Tablet
7
PAHANG PHARMACY SDN BHD
Malaysia
1
$107K
MYLAN LABORATORIES LTD
Tablet
8
AUROBINDO PHARMA COLOMBIA SAS
Colombia
1
$56K
AUROBINDO PHARMA LTD
Tablet
9
AUROLOGISTICS LLC
United States
1
$29K
AUROBINDO PHARMA LTD
Tablet
10
SUN PHARMACEUTICALS MOROCCO LLC
Morocco
1
$28K
SUN PHARMACEUTICAL I…
Tablet
11
CENTRAL PHARMACEUTICAL CPC
Vietnam
1
$25K
MACLEODS PHARMACEUTI…
Tablet
12
PROJECT MANAGEMENT UNIT
Eritrea
1
$8K
MACLEODS PHARMACEUTI…
Tablet
13
KARMA PHARMACEUTICALS LTD
Zambia
1
$5K
CIPLA LTD
Tablet
14
SOGUIPREM
Guinea
1
$2K
SIDDHIVINAYAK DISTRI…
Tablet
15
OYA PHARMA
Libya
4
$1K
CIPLA LTD
Tablet
16
NEW GPC INC
Guyana
1
$692.53
H V A INTERNATIONAL
Tablet
17
DEPARTMENT OF HEALTH
Myanmar
1
$343.63
MICRO LABS LTD
Tablet
18
MINISTRY OF HEALTH OF THE
Azerbaijan
2
$49.33
MACLEODS PHARMACEUTI…
Tablet
19
EMIRATES POST COMPANY
United Arab Emirates
2
$47.72
DERRIC WOOD
Tablet
20
ATLANTA MEDICARE CO LTD
Thailand
1
$37.90
MYLAN LABORATORIES LTD
Tablet
21
ZEYTUN PHARMACEUTICALS LLC
Azerbaijan
1
$17.47
SUN PHARMACEUTICAL I…
Tablet
This report covers 47 2025-Q4 Efavirenz shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/efavirenz
Talk to our trade analyst
Need a custom efavirenz report or a deeper dive into any market? Our team is ready.